Mahar Alyson L, Biggs Kelly, Hansford Rebecca L, Derksen Shelley, Griffiths Rebecca, Enns Jennifer E, Dawe David E, Hallet Julie, Kristjanson Mark, Decker Kathleen, Cobigo Virginie, Shooshtari Shahin, Stirling Morgan, Kelly Christine, Brownell Marni, Turner Donna, Ouellette-Kuntz Hélène
Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada.
School of Nursing, Queen's University, Kingston, Ontario, Canada.
Cancer. 2024 Mar 1;130(5):740-749. doi: 10.1002/cncr.35068. Epub 2023 Oct 30.
Cancer is a leading cause of death among people living with intellectual or developmental disabilities (IDD). Although studies have documented lower cancer screening rates, there is limited epidemiological evidence quantifying potential diagnostic delays. This study explores the risk of metastatic cancer stage for people with IDD compared to those without IDD among breast (female), colorectal, and lung cancer patients in Canada.
Separate population-based cross-sectional studies were conducted in Ontario and Manitoba by linking routinely collected data. Breast (female), colorectal, and lung cancer patients were included (Manitoba: 2004-2017; Ontario: 2007-2019). IDD status was identified using established administrative algorithms. Modified Poisson regression with robust error variance models estimated associations between IDD status and the likelihood of being diagnosed with metastatic cancer. Adjusted relative risks were pooled between provinces using random-effects meta-analyses. Potential effect modification was considered.
The final cohorts included 115,456, 89,815, and 101,811 breast (female), colorectal, and lung cancer patients, respectively. Breast (female) and colorectal cancer patients with IDD were 1.60 and 1.44 times more likely to have metastatic cancer (stage IV) at diagnosis compared to those without IDD (relative risk [RR], 1.60; 95% confidence interval [CI], 1.16-2.20; RR, 1.44; 95% CI, 1.24-1.67). This increased risk was not observed in lung cancer. Significant effect modification was not observed.
People with IDD were more likely to have stage IV breast and colorectal cancer identified at diagnosis compared to those without IDD. Identifying factors and processes contributing to stage disparities such as lower screening rates and developing strategies to address diagnostic delays is critical.
癌症是智力或发育障碍(IDD)患者的主要死因之一。尽管研究记录了较低的癌症筛查率,但量化潜在诊断延迟的流行病学证据有限。本研究探讨了在加拿大乳腺癌(女性)、结直肠癌和肺癌患者中,IDD患者与非IDD患者相比发生转移性癌症阶段的风险。
通过链接常规收集的数据,在安大略省和曼尼托巴省分别进行了基于人群的横断面研究。纳入乳腺癌(女性)、结直肠癌和肺癌患者(曼尼托巴省:2004 - 2017年;安大略省:2007 - 2019年)。使用既定的行政算法确定IDD状态。采用稳健误差方差模型的修正泊松回归估计IDD状态与被诊断为转移性癌症可能性之间的关联。使用随机效应荟萃分析汇总各省调整后的相对风险。考虑了潜在的效应修饰。
最终队列分别包括115456例、89815例和101811例乳腺癌(女性)、结直肠癌和肺癌患者。与非IDD患者相比,患有IDD的乳腺癌(女性)和结直肠癌患者在诊断时发生转移性癌症(IV期)的可能性分别高出1.60倍和1.44倍(相对风险[RR],1.60;95%置信区间[CI],1.16 - 2.20;RR,1.44;95%CI,1.24 - 1.67)。在肺癌中未观察到这种风险增加。未观察到显著的效应修饰。
与非IDD患者相比,IDD患者在诊断时更有可能被确定患有IV期乳腺癌和结直肠癌。识别导致阶段差异的因素和过程,如较低的筛查率,并制定应对诊断延迟的策略至关重要。